ASIATODAY

BIZ&TECH

MedPacto says U.S. FDA approves additional dose in Phase 2 osteosarcoma trial

MedPacto announced on the 19th that it received approval from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) protocol amendment to add a medium-dose patient cohort in the Phase 2 clinical trial of Vactosertib, a treatment for osteosarcoma, a rare bone cancer. The clinical trial is currently underway simultaneously in South..

Why Starbucks continues store expansion into second half of year
Starbucks is pressing ahead with new store openings in the second half of the year despite sluggish earnings. Having opened around 90 new stores in the fir..

previous block

11 12 13 14 15 16 17 18 19 20

next block

Most Read

1

Celltrion nears additional contract with major U.S..

2

"Aren't those foreigners on welfare?": M..

3

U.S. weighs dropping MOAB, world's most powerful n..

4

Houthis launch successive attacks on Saudi airport..

5

Saudi Arabia, Iran hold first diplomatic talks to..

6

Saudi airport in Riyadh struck again, leaving at l..

7

Five ASEAN countries welcome Myanmar coup leader

PEOPLE

"Hallyu ban to be removed quickly": Hopes of thaw in Seoul-Beijing ties: · "Efforts will be made to remove Hallyu ban quickly"; · SK Group Chairman heads to Japan to soften "WD risk"

PHOTO

Jang Won-young shines as BVLGARI’s holiday muse

S.KOREA

POLITICS

SOCIAL AFFAIRS

WORLD

CHINA

INDIA

OTHERS

ECONOMY

BIZ&TECH

CULTURE

PEOPLE

PHOTO

Address : In-Young Bldg., 34, Uisadang-daero 1-gil, Yeongdeungpo-gu, Seoul

Copyright by ASIATODAY CO., LTD. All rights resereved